News coverage about Seres Therapeutics (NASDAQ:MCRB) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seres Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.6436147256432 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Seres Therapeutics : Roseville-based Rebiotix in race to develop therapy for deadly intestinal infection (4-traders.com)
- ArQule, Inc. (ARQL) has a value of $1.05 per share While Seres Therapeutics, Inc. (MCRB) is stand at $13.33 - Stocks Gallery (stocksgallery.com)
- Seres Therapeutics, Inc. (NASDAQ:MCRB) Stock Traded 4.7% Above Its 50 Day Moving Average - Highlight Press (highlightpress.com)
- Seres Therapeutics, Inc. (MCRB) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Seres Therapeutics, Inc. (NASDAQ:MCRB) Stock Traded 5.5% Above Its 50 Day Average - First News 24 (firstnewspaper24.com)
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 2.93% during mid-day trading on Friday, hitting $12.94. 160,677 shares of the stock were exchanged. The stock’s 50 day moving average is $12.77 and its 200 day moving average is $10.81. The firm’s market cap is $524.23 million. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.10. The business had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. Seres Therapeutics’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) EPS. Analysts expect that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.
MCRB has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Wednesday, July 5th. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Friday, May 19th. Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $17.00.
ILLEGAL ACTIVITY WARNING: “Seres Therapeutics (MCRB) Earns Daily News Sentiment Rating of 0.15” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://stocknewstimes.com/2017/08/19/seres-therapeutics-mcrb-earns-daily-news-sentiment-rating-of-0-15.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
